UPDATED: NICE turns down Opdivo for lung cancer : fiercepharma

As it stated in fiercepharma

UPDATED: NICE turns down Opdivo for lung cancer

UPDATED: NICE turns down Opdivo for lung cancer

Bristol-Myers Squibb ($BMY) has gotten more bad news in its efforts to grow lung cancer sales.England's cost watchdog has turned it down, although the regulator did offer up a tidbit of support.NICE has told the company that the immuno-oncology treatment is not cost effective enough for previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).But in a sliver of hope, NICE told the drugmaker it should seek approval through the country's Cancer Drugs Fund for patients that test for the PD-L1 biomarker.


in addition express

Thousands of lung cancer patients 'denied life-extending drug on NHS'

Thousands of lung cancer patients 'denied life-extending drug on NHS'

GETTY NICE have announced it will not be funding the breakthrough immunotherapy drug nivolumabDrugs funding body NICE (National Institute for Health and Care Excellence) today announced that it will not be recommending the breakthrough immunotherapy drug nivolumab for advanced lung cancer patients in England and Wales.Doctors say the decision will come as "bitter blow" to families in England and Wales who have been waiting for months to get access to the revolutionary treatment which was approved for patients in Scotland last week.Immunotherapy has been hailed by experts as one of the most important advances in lung cancer treatment in the past decade.Around 45,500 are diagnosed with the condition every year in the UK and it is the third most common cancer.


as well foxnews

Changes in depression symptoms tied to lung cancer survival

Changes in depression symptoms tied to lung cancer survival

Worsening depression symptoms are associated with shorter survival for lung cancer patients, particularly those in the early stages of disease, according to a new U.S. study.Conversely, when depression symptoms lift, survival tends to improve, researchers found."Surprisingly, depression remission was associated with a mortality benefit as they had the same mortality as never-depressed patients," said lead author Donald R. Sullivan of Oregon Health and Science University in Portland."This study cannot prove causation - but it lends support to the idea that surveillance for depression symptoms and treatment for depression could provide significant impact on patient outcomes, perhaps even a mortality benefit," he told Reuters Health by email.